<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03900299</url>
  </required_header>
  <id_info>
    <org_study_id>multifocal breast cancer2018</org_study_id>
    <nct_id>NCT03900299</nct_id>
  </id_info>
  <brief_title>Evaluating New Surgical Technique in Management of Female Patients With Operable Multifocal Breast Cancer</brief_title>
  <official_title>Tailoring Surgical Management of Multifocal Breast Cancer:is There a Possibility</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alexandria University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Alexandria University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Multi-focal Breast Cancers(MFBC) still have undiscoverable Clinical Significance reflecting&#xD;
      on a debatable surgical decision for this Category of breast cancer. A prospective study was&#xD;
      conducted using certain surgical technique as a surgical treatment for female patients with&#xD;
      operable breast cancer managed at the Surgical Oncology Unit, Alexandria University from May.&#xD;
      2017 to May2018 and will be followed for 3 Years.Analysis will be done to settle a paradigm&#xD;
      for surgical management of Multi-focal Breast Cancer&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      -  Age at diagnosis: young patients are defined as younger than 35 years.&#xD;
&#xD;
        -  Surgical techniques: Preoperatively all patients will undergo physical examination of&#xD;
           both breasts and axillae as well as bilateral mammograms and ultrasonography of both&#xD;
           breasts. Histopathological diagnosis of cancer will be made prior to surgery. The&#xD;
           planned procedure will be discussed. Different oncoplastic techniques will be utilized&#xD;
           to achieve oncologically appropriate margins with either sentinel lymph node detection&#xD;
           or axillary lymph node dissection according to the triple assessment of the patients .&#xD;
           Surgical margins were determined by macroscopic and histologic examination of frozen&#xD;
           sections of the breast specimens in the operating room. An adequate safety margin of 1cm&#xD;
           was always insured. Breast remodeling will be done according to breast size, degree of&#xD;
           ptosis and size of defect.&#xD;
&#xD;
        -  Tumor characteristics: size, nodal status, presence of lympho-vascular invasion, amount&#xD;
           of intraductal component, tumor grade, margin status, hormone receptor, and Her2 neu&#xD;
           status.&#xD;
&#xD;
        -  Margins will be regarded as negative when permanent histological examination found no&#xD;
           ink on the tumor.&#xD;
&#xD;
        -  Postoperative surgical complications will be documented if happened; seroma formation,&#xD;
           hematoma and or wound dehiscence.&#xD;
&#xD;
        -  Cosmetic outcome: The postoperative esthetic result will be evaluated asking the&#xD;
           patients to rate the postoperative cosmetic result and their degree of satisfaction&#xD;
           compared to the preoperative breast using a five-point scale (excellent, 5; good, 4;&#xD;
           fair, 3; poor, 2;bad, 1). Objective assessment of the cosmetic result was done by two&#xD;
           surgeons, rated on a visual analog scale from 1 (unacceptable result) to 10 (excellent&#xD;
           result). Evaluation is based on 5 criteria, namely: breast symmetry, glandular tissue&#xD;
           defects, nipple and areola reconstruction, scar quality and/or retraction, and the&#xD;
           resultant breast shape. (14)&#xD;
&#xD;
        -  The occurrence of loco-regional recurrence or distant metastases during the follow-up&#xD;
           period was recorded and considered as an end point for follow-up.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">May 1, 2017</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Actual">May 1, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>All operable(don't require neoadjuvant therapy or inflammatory carcinoma) female patients diagnosed as multifocal breast cancer will receive oncoplastic breast surgery as a surgical treatment.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Recurrence of the Tumor</measure>
    <time_frame>a median of 30 months post operative</time_frame>
    <description>assessment of the occurrence of local or distant recurrence through:&#xD;
monthly clinical examination of both breast and axillae&#xD;
monthly liver functions tests and complete blood count&#xD;
radiological assessment if clinically indicated</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cosmetic Result</measure>
    <time_frame>a median of 30 months post operative</time_frame>
    <description>assessment of breast cosmesis after oncoplastic surgical intervention.Evaluation is based on 5 criteria, namely: breast symmetry, glandular tissue defects, nipple and areola reconstruction, scar quality and/or retraction, and the resultant breast shape.&#xD;
each criteria will be evaluated either satisfactory or not,satisfactory evaluation will represent 1 point.&#xD;
unsatisfactory will represent 0 point excellent result is equal or more than 4 points good result is equal to 3 points fair result is equal to 2 points bad result is equal to 1 point or less</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">114</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>oncoplastic breast surgery</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>oncoplastic breast surgery</intervention_name>
    <description>oncoplastic breast surgery with level 1 or 2 according to the case using intra operative frozen section to assess the margin</description>
    <arm_group_label>oncoplastic breast surgery</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  all operable female patients affected with multifocal breast cancer&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  inflammatory breast cancer&#xD;
&#xD;
          -  patients need receiving neoadjuvant therapy&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>all operable female patients affected with multifocal breast cancer</gender_description>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ahmed T. Awad, MD</last_name>
    <role>Study Director</role>
    <affiliation>professor of surgical oncology,Alexandria university</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mostafa M. Elsayed, Msc</last_name>
    <role>Principal Investigator</role>
    <affiliation>Surgical oncology registrar,Alexandria university</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Faculty of medicine ,Alexandria university</name>
      <address>
        <city>Alexandria</city>
        <zip>21500</zip>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <results_reference>
    <citation>Yerushalmi R, Kennecke H, Woods R, Olivotto IA, Speers C, Gelmon KA. Does multicentric/multifocal breast cancer differ from unifocal breast cancer? An analysis of survival and contralateral breast cancer incidence. Breast Cancer Res Treat. 2009 Sep;117(2):365-70. doi: 10.1007/s10549-008-0265-1. Epub 2008 Dec 11.</citation>
    <PMID>19082705</PMID>
  </results_reference>
  <results_reference>
    <citation>Gentilini O, Botteri E, Rotmensz N, Da Lima L, Caliskan M, Garcia-Etienne CA, Sosnovskikh I, Intra M, Mazzarol G, Musmeci S, Veronesi P, Galimberti V, Luini A, Viale G, Goldhirsch A, Veronesi U. Conservative surgery in patients with multifocal/multicentric breast cancer. Breast Cancer Res Treat. 2009 Feb;113(3):577-83. doi: 10.1007/s10549-008-9959-7. Epub 2008 Mar 11.</citation>
    <PMID>18330695</PMID>
  </results_reference>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>March 20, 2019</study_first_submitted>
  <study_first_submitted_qc>April 1, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 3, 2019</study_first_posted>
  <results_first_submitted>September 20, 2019</results_first_submitted>
  <results_first_submitted_qc>January 16, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">January 21, 2020</results_first_posted>
  <last_update_submitted>July 15, 2020</last_update_submitted>
  <last_update_submitted_qc>July 15, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 29, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Alexandria University</investigator_affiliation>
    <investigator_full_name>mostafa mohamed elsayed</investigator_full_name>
    <investigator_title>registrar of surgical oncology and general surgery</investigator_title>
  </responsible_party>
  <keyword>breast conservative surgery</keyword>
  <keyword>oncoplastic breast surgery</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>IPD will be available that underlie results in a publication</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_time_frame>will be available for 1 year after publication</ipd_time_frame>
    <ipd_access_criteria>individual participant data will be available to every researcher in field of multi -focal breast cancer, the candidate should have an accepted protocol from the ethical committee of the organization. contacting the main investigator will be method to review the request</ipd_access_criteria>
    <ipd_url>http://www.med.alexu.edu.eg/ethics-committee/</ipd_url>
  </patient_data>
  <study_docs>
    <study_doc>
      <doc_type>Study Protocol</doc_type>
      <doc_url>http://www.med.alexu.edu.eg/ethics-committee/</doc_url>
    </study_doc>
  </study_docs>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>January 1, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/99/NCT03900299/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>December 2, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/99/NCT03900299/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Multifocal Breast Cancer Patients Treated Surgically by MRM</title>
          <description>multifocal breast cancer patients involved in the study will be randomized to be treated either by oncoplastic breast conserving surgery or modified radical mastectomy(MRM)</description>
        </group>
        <group group_id="P2">
          <title>Multifocal Breast Cancer Patients Treated Surgically by OPS</title>
          <description>multifocal breast cancer patients involved in the study randomized in the setting of receiving surgical treatment either modified radical mastectomy (MRM) or oncoplastic breast surgery(OPS)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="56"/>
                <participants group_id="P2" count="58"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="56"/>
                <participants group_id="P2" count="58"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Multifocal Breast Cancer Patients Treated Surgically by MRM</title>
          <description>multifocal breast cancer patients involved in the study will be randomized to be treated either by oncoplastic breast conserving surgery or modified radical mastectomy(MRM)</description>
        </group>
        <group group_id="B2">
          <title>Multifocal Breast Cancer Patients Treated Surgically by OPS</title>
          <description>multifocal breast cancer patients involved in the study randomized in the setting of receiving surgical treatment either modified radical mastectomy (MRM) or oncoplastic breast surgery(OPS)</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="56"/>
            <count group_id="B2" value="58"/>
            <count group_id="B3" value="114"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <description>Age in years&#xD;
&lt; 40 40- 50- 60+</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>&lt;40</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="56"/>
                    <count group_id="B2" value="58"/>
                    <count group_id="B3" value="114"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>40-49</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="56"/>
                    <count group_id="B2" value="58"/>
                    <count group_id="B3" value="114"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>50-59</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="56"/>
                    <count group_id="B2" value="58"/>
                    <count group_id="B3" value="114"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>60+</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="56"/>
                    <count group_id="B2" value="58"/>
                    <count group_id="B3" value="114"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="56"/>
                    <count group_id="B2" value="58"/>
                    <count group_id="B3" value="114"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="56"/>
                    <measurement group_id="B2" value="58"/>
                    <measurement group_id="B3" value="114"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Egypt</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="56"/>
                    <count group_id="B2" value="58"/>
                    <count group_id="B3" value="114"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="56"/>
                    <measurement group_id="B2" value="58"/>
                    <measurement group_id="B3" value="114"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>tumor size</title>
          <description>T(TUMOR SIZE) T1 &lt;2 cm T2 (2-5 cm) T3 &gt; 5 cm T4 tumor attached to the skin</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>T1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="56"/>
                    <count group_id="B2" value="58"/>
                    <count group_id="B3" value="114"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="34"/>
                    <measurement group_id="B3" value="57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="56"/>
                    <count group_id="B2" value="58"/>
                    <count group_id="B3" value="114"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="56"/>
                    <count group_id="B2" value="58"/>
                    <count group_id="B3" value="114"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Recurrence of the Tumor</title>
        <description>assessment of the occurrence of local or distant recurrence through:&#xD;
monthly clinical examination of both breast and axillae&#xD;
monthly liver functions tests and complete blood count&#xD;
radiological assessment if clinically indicated</description>
        <time_frame>a median of 30 months post operative</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Multifocal Breast Cancer Patients Treated Surgically by MRM</title>
            <description>multifocal breast cancer patients involved in the study will be randomized to be treated either by oncoplastic breast conserving surgery or modified radical mastectomy(MRM)</description>
          </group>
          <group group_id="O2">
            <title>Multifocal Breast Cancer Patients Treated Surgically by OPS</title>
            <description>multifocal breast cancer patients involved in the study randomized in the setting of receiving surgical treatment either modified radical mastectomy (MRM) or oncoplastic breast surgery(OPS)</description>
          </group>
        </group_list>
        <measure>
          <title>Recurrence of the Tumor</title>
          <description>assessment of the occurrence of local or distant recurrence through:&#xD;
monthly clinical examination of both breast and axillae&#xD;
monthly liver functions tests and complete blood count&#xD;
radiological assessment if clinically indicated</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="56"/>
                <count group_id="O2" value="58"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Tumor recurrence</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>no tumor recurrence</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54"/>
                    <measurement group_id="O2" value="55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cosmetic Result</title>
        <description>assessment of breast cosmesis after oncoplastic surgical intervention.Evaluation is based on 5 criteria, namely: breast symmetry, glandular tissue defects, nipple and areola reconstruction, scar quality and/or retraction, and the resultant breast shape.&#xD;
each criteria will be evaluated either satisfactory or not,satisfactory evaluation will represent 1 point.&#xD;
unsatisfactory will represent 0 point excellent result is equal or more than 4 points good result is equal to 3 points fair result is equal to 2 points bad result is equal to 1 point or less</description>
        <time_frame>a median of 30 months post operative</time_frame>
        <population>overall number of participants subjected to oncoplastic breast surgery is 58 subdivided to categories according to the oncoplastic technique used, totally 58 patients</population>
        <group_list>
          <group group_id="O1">
            <title>Oncoplastic Breast Surgery</title>
            <description>oncoplastic breast surgery: oncoplastic breast surgery with level 1 or 2 according to the case using intra operative frozen section to assess the margin</description>
          </group>
        </group_list>
        <measure>
          <title>Cosmetic Result</title>
          <description>assessment of breast cosmesis after oncoplastic surgical intervention.Evaluation is based on 5 criteria, namely: breast symmetry, glandular tissue defects, nipple and areola reconstruction, scar quality and/or retraction, and the resultant breast shape.&#xD;
each criteria will be evaluated either satisfactory or not,satisfactory evaluation will represent 1 point.&#xD;
unsatisfactory will represent 0 point excellent result is equal or more than 4 points good result is equal to 3 points fair result is equal to 2 points bad result is equal to 1 point or less</description>
          <population>overall number of participants subjected to oncoplastic breast surgery is 58 subdivided to categories according to the oncoplastic technique used, totally 58 patients</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="58"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>theraputic lateral mammoplasty</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>excellent cosmetic result</title>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                  </measurement_list>
                </category>
                <category>
                  <title>very good cosmetic result</title>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>round block</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="14"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>excellent cosmetic result</title>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                  </measurement_list>
                </category>
                <category>
                  <title>very good cosmetic result</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>parallelogram mastopxy</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>excellent cosmetic result</title>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>very good cosmetic result</title>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>V theraputic mammoplasty</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>excellent cosmetic result</title>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>very good cosmetic result</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Latissimus Dorsi flap</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>excellent cosmetic result</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>very good cosmetic result</title>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>J theraputic mammoplasty</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>excellent cosmetic result</title>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>very good cosmetic result</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>grisotti flap</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>excellent cosmetic result</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>very good cosmetic result</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>reduction therapeutic mammoplasty</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>excellent cosmetic result</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>very good cosmetic result</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>through 24 months post operative</time_frame>
      <desc>Early complications&#xD;
Haematoma&#xD;
Seroma&#xD;
Abcess&#xD;
Skin or NAC necrosis&#xD;
Late complications&#xD;
Scar fibrosis&#xD;
keloid&#xD;
steatonecrosis</desc>
      <group_list>
        <group group_id="E1">
          <title>Multifocal Breast Cancer Patients Treated Surgically by MRM</title>
          <description>multifocal breast cancer patient treated by modified radical mastectomy(MRM) 66 patients&#xD;
Early complications Haematoma 2 patients out of 56 Seroma 16 patients out of 56 Skin or flap necrosis 5 patients out of 56 Abcess 3 patients out of 56&#xD;
Late complications Scar fibrosis 2 patients out of 56 keloid 1 patients out of 56</description>
        </group>
        <group group_id="E2">
          <title>Multifocal Breast Cancer Patients Treated Surgically by OPS</title>
          <description>multifocal breast cancer patients treated by oncoplastic breast surgery(OPS) 58 patients&#xD;
Early complications Haematoma 2 patients out of 58 Seroma 10 patients out of 58 Abcess 4 patients out of 58 Skin or NAC necrosis 2 patients out of 58&#xD;
Late complications Scar fibrosis 3 patients out of 58 keloid 2 patients out of 58 steatonecrosis 5 patients out of 58</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="56"/>
                <counts group_id="E2" subjects_affected="28" subjects_at_risk="58"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Haematoma</sub_title>
                <description>Early post operative complication</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="56"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Seroma</sub_title>
                <description>Early post operative complications</description>
                <counts group_id="E1" events="16" subjects_affected="16" subjects_at_risk="56"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>skin necrosis</sub_title>
                <description>Early post operative complications</description>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="56"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>abcess</sub_title>
                <description>early post operative</description>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="56"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Scar fibrosis</sub_title>
                <description>Late post operative complications</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="56"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>keloid</sub_title>
                <description>late post operative complications</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="56"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>steatonecrosis</sub_title>
                <description>late post operative complications</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="58"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="58"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>DR. mostafa elsayed</name_or_title>
      <organization>Alexandria university</organization>
      <phone>560566541 ext +966</phone>
      <email>m_elsayed2009@yahoo.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

